Galenica continues growth trajectory and confirms outlook for 2026

Galenica continued its growth trajectory in the first nine months of 2026 and increased sales by 5.7% to CHF 3,172.0 million. The main drivers were the continued positive performance in the pharmacy business, strong growth in the home care sector and the integration of the Diagnostics business segment. Temporary restrictions on the product range during the ERP migration resulted in weaker growth in the wholesale business in the third quarter.

Julian Fiessinger, CFO of Galenica, sums up the sales result: “We continued our growth trajectory in the high-margin Products & Care segment in the third quarter. The good performance of our pharmacy business and the strong growth in the home care sector are particularly pleasing. Following the successful ERP switchover, we also expect to see higher growth momentum again in wholesale in the fourth quarter. We are therefore still on track to achieve our guidance.”
 

Pharmacy business continues to develop positively

The Pharmacies Omni-channel business segment continued its positive development, increasing net sales by 6.2% to CHF 1,134.5 million, with organic growth of 4.5%. Sustained strong demand for prescription-only medication once again proved to be a growth driver. These include, in particular, GLP-1-based weight loss products and medications for the treatment of rheumatic diseases. Taking into account the product mix (Rx and OTC products: +5.3%2, non-drugs segment in the consumer healthcare market: +1.1%3), this results in further market share gains for Galenica pharmacies.

Demand for fee-based advisory and healthcare services also continued to increase: Around 290,000 such services were provided in the first nine months (+26%), including 34,000 vaccinations.
 

Consumer healthcare market remains competitive

The Products & Brands business segment generated net sales of CHF 136.5 million (-7.2%), driven in particular by seasonal factors as well as adverse one-off effects in the international business. Due to the portfolio’s focus on flu and cold products, market sales of Verfora products declined by 2.4% in a challenging market environment. By comparison, the Swiss market for over-the-counter healthcare products remained flat, growing by 0.3%3 in the first nine months of 2026.
 

Strong growth in Home Care, continued positive performance in the Diagnostics segment

The Services & Production business segment performed positively in the first nine months of 2026, increasing net sales by 5.8% to CHF 93.6 million; excluding the impact of the closure of Bichsel’s pharmaceutical production operations, growth amounted to 10.5%. The home care business of Bichsel, Lifestage Solutions and Medifilm was once again a key driver of growth. The Diagnostics business segment also continued to develop positively, contributing CHF 91.6 million to the Galenica Group’s net sales in the first nine months of 2026.
 

Successful ERP migration at Galexis

Galexis reached an important milestone in its wholesale business with the successful ERP migration at the Niederbipp site. The final implementation step was completed in September and the foundations were laid for the further development of logistics services and for further increasing automation and efficiency in the wholesale business. The temporary product range restrictions associated with the switchover led to a slowdown in growth in the third quarter. Galenica expects higher growth momentum again in the fourth quarter.

The wholesale business segment generated net sales of CHF 2,441.3 million (+2.8%). In the same period, the overall pharmaceutical market grew by 3.5%2, while the physicians segment generated growth of 2.7%2, and the bricks-and-mortar pharmacy segment grew by 5.3%2. The Logistics & IT Services business segment generated net sales of CHF 58.6 million, representing a slight increase of 0.5% year on year.
 

2026 outlook confirmed

Galenica confirms its outlook for the 2026 financial year, with sales growth of between 5% and 7%, adjusted EBIT1 growth of between 6% and 8% and a dividend at least equal to the previous year’s level.

 

Net sales of the Galenica Group January – September 2026
 

(in million CHF)

Sept. 2026

Sept. 2025

Change

Products & Care segment

1,446.3

1,304.4

10.9%

Pharmacies Omni-Channel

1,134.5

1,068.0

6.2%

Products & Brands

136.5

147.1

-7.2%

Services & Production

93.6

88.4

5.8%

Diagnostics

91.6

7.9

 

Logistics & IT segment

2,498.0

2,432.2

2.7%

Wholesale

2,441.3

2,375.9

2.8%

Logistics & IT Services

58.6

58.4

0.5%

Corporate and eliminations

-772.4

-736.9

 

Galenica Group

3,172.0

2,999.7

5.7%

 

__________

1 See definition in the chapter “Alternative performance measures” in the Annual Report 2025.

2 IQVIA, Pharmaceutical Market Switzerland, YTD September 2026.

3 IQVIA, Consumer Health Market Switzerland, YTD September 2026.

 

 

Additional information on sales figures, explanations of the approach to sales presentation and further information can be found in our sales presentation.

Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance

Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance




Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance

Ad hoc announcement pursuant to Art. 53 LR


ZUG, Switzerland–(BUSINESS WIRE)–Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026.

  • Record net sales of 4.765 billion USD for the first nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix.
  • Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma’s proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators.
  • Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio net sales of 735 million USD).
  • Strengthening Galderma’s dermatology platform, with the previously announced agreement to acquire ZO® Skin Health, a leading brand in the fast-growing physician-dispensed skincare category. The transaction is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and other customary closing conditions.
  • Further evolution as a listed company, with Galderma’s inclusion in the Swiss Market Index (SMI) and an upgraded credit rating.
  • Raising 2026 full-year net sales guidance to 22.5-23.5% growth year-on-year at constant currency (previously 19-21%), and confirming Core EBITDA margin2 of approximately 26% at constant currency.

 

“Our strong performance in the first nine months of 2026 underscores the sustained momentum across our business and the strength of our integrated dermatology strategy. Robust demand for our differentiated, premium portfolio continues to drive growth, while we advance innovation and take decisive steps to strengthen our long-term growth prospects, including our agreement to acquire ZO Skin Health. Building on this momentum and our confidence in the business, we are raising our full-year net sales guidance.”

 

FLEMMING ØRNSKOV, M.D., MPH

CHIEF EXECUTIVE OFFICER

GALDERMA

 

Commercial performance

For the first nine months of 2026, Galderma achieved record net sales of 4,765 million USD, with year-on-year growth of 25.1% at constant currency. Through focused execution of its proven, growth-driven integrated dermatology strategy, Galderma continued to deliver double-digit net sales growth in most of its top 10 markets.

Growth was broad-based across the existing portfolio, complemented by innovation and further increasing penetration in fast-growing, attractive markets. Performance was particularly strong in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators. Growth continued to be predominantly driven by volume, complemented by favorable mix.

Net sales growth of 26.0% year-on-year at constant currency in the third quarter was supported by continued market outperformance across all product categories and market conditions that remained more resilient than expected. Galderma continued to benefit from sustained consumer demand and preference, particularly through its premium positions in Injectable Aesthetics and Dermatological Skincare.

Injectable Aesthetics

Injectable Aesthetics net sales for the first nine months were 2,174 million USD, with year-on-year growth of 13.2% at constant currency.

Neuromodulators delivered net sales of 1,259 million USD, up 16.9% year-on-year at constant currency. Galderma continued to gain market share in both the U.S. and International markets. With the Group’s proven Neuromodulator portfolio strategy, Dysport® continued to grow in all top markets while the launch of Relfydess™ continued to build momentum in Europe and Asia Pacific. In addition to the continued strong momentum globally for Neuromodulators, growth in the third quarter was supported by the unwinding of the U.S. phasing effects from the second quarter.

Galderma continued to make progress in expanding Relfydess’ global regulatory footprint, with approvals now secured in 37 markets and regulatory reviews ongoing in additional territories. In the U.S., Galderma is targeting the first quarter of 2027 to resubmit the Biologics License Application (BLA) for RelabotulinumtoxinA to the Food and Drug Administration (FDA), following receipt of a Complete Response Letter (CRL) in June 2026, subject to further regulatory feedback.

On September 29, 2026, Galderma filed confidential arbitration proceedings with the International Chamber of Commerce (ICC) and the American Arbitration Association (AAA) with respect to certain rights and obligations between Galderma and Ipsen, including Galderma’s exclusive rights in the aesthetics field and other matters relating to Ipsen’s Long-Acting NeuroToxin clinical program (LANTIC). These filings do not concern Dysport/Azzalure®, Alluzience®, and Relfydess.

Fillers & Biostimulators achieved net sales of 914 million USD, up 8.5% year-on-year at constant currency, despite continued softness in the Fillers market. Galderma continued to gain share in both the U.S. and International markets in Fillers & Biostimulators, with continued double-digit growth for Sculptra® in both geographies. The portfolio benefited from further expansion, supported by leadership in science and education, and strong commercial execution. As anticipated, third quarter growth was impacted by a high base in the second half of the previous year.

Dermatological Skincare

Dermatological Skincare net sales for the first nine months were 1,244 million USD, with year-on-year growth of 16.2% at constant currency.

Momentum remained strong across both Dermatological Skincare flagship brands, Cetaphil® and Alastin®. Growth was positive in both the U.S. and International markets, with e-commerce remaining the fastest growing channel globally. Cetaphil growth was driven particularly by fast-growing International markets and especially Asia. Alastin delivered double-digit growth in both geographies, with continued penetration in the U.S. and geographic expansion.

Galderma continued to outperform the market, driven by disciplined execution against strong fundamentals: strong core brand equity through differentiated science and portfolio synergies, focus on the core portfolio while continuing to invest in innovation, and locally relevant activation through campaigns that build awareness of its brands. Key innovations included the U.S. expansion of Cetaphil’s Nourishing line into body care and the launch of Alastin’s Restorative Eye Complex with TriHex+™ technology.

Therapeutic Dermatology

Therapeutic Dermatology net sales for the first nine months were 1,347 million USD, up 64.4% year-on-year at constant currency.

Nemluvio net sales for the first nine months were 735 million USD. The strong trajectory reflects continued demand growth, particularly among treatment-naïve patients and disciplined commercial execution.

The U.S. represents the vast majority of Nemluvio sales, with a greater contribution from atopic dermatitis than prurigo nodularis. In the U.S., Nemluvio paid new patient starts (NBRx)3 from the first week of September to the second week of October 2026 trended at approximately 45% market share in prurigo nodularis and approximately 9% in atopic dermatitis. For the same period, Nemluvio’s total paid prescription share (TRx)3 in the U.S. trended at approximately 37% in prurigo nodularis and approximately 5% in atopic dermatitis. Nemluvio in International markets also continued to perform ahead of expectations and to progress with its expansion, with approvals for both moderate-to-severe atopic dermatitis and prurigo nodularis in more than 40 countries as well as further regulatory reviews ongoing.

The mature Therapeutic Dermatology portfolio continued to show positive growth, with impact from generic entries slower-than-expected. Differin® growth was also strong globally and especially in the U.S., with continued uptake from the recent Differin Epiduo® Acne Gel Prescription-to-OTC (over-the-counter) switch in acne care.

Science-led innovation in dermatology

Galderma continued to advance its science-led innovation and medical education agenda.

In Injectable Aesthetics, Galderma strengthened the clinical evidence of its portfolio with new positive topline data for Restylane® Volyme™ for temple hollowing in support of plans to expand presence in China, and interim data for an investigator-initiated trial demonstrating that Restylane Skinboosters™ and Sculptra drove progressive improvements in hydration, skin barrier function, and skin quality in menopausal women.

In Dermatological Skincare, Galderma continued to take steps to expand its portfolio, both organically through differentiated innovation and externally through the previously announced agreement to acquire ZO Skin Health, subject to regulatory approvals and other customary closing conditions.

In Therapeutic Dermatology, new three-year ARCADIA long-term extension data reinforced Nemluvio’s durable efficacy and favorable tolerability profile in adults and adolescents with moderate-to-severe atopic dermatitis. Clinically meaningful improvements in eczema severity, near-complete skin clearance, itch, and quality of life at Week 152 were presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and at the Fall Clinical Dermatology 2026.

Galderma also continued to broaden the clinical development program for nemolizumab across additional patient populations and potential indications. This includes progressing the submission preparation of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis in the U.S., noting new phase II data presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. Galderma also initiated a study in infants and young children aged 6 months to under 2 years with moderate-to-severe atopic dermatitis. Recruitment was also completed in the phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO) with topline results expected in the first quarter of 2027.

ZO Skin Health acquisition

ZO Skin Health was founded in 2007 by world-renowned dermatologist Dr. Zein Obagi and, in 2020, Blackstone acquired a majority stake. Today, ZO Skin Health represents a highly strategic and financially attractive opportunity for Galderma. With a leading science-based, physician-endorsed portfolio and global presence complementary to Alastin’s, ZO Skin Health would enable Galderma to expand its Dermatological Skincare offering in this attractive, fast-growing segment. Galderma’s proven integrated dermatology platform provides complementarity, synergies, and scale with the ambition to reignite ZO Skin Health’s growth, creating an additional long-term growth driver for Galderma while maintaining financial discipline.

The acquisition of ZO Skin Health, for an enterprise value of 1.5 billion USD in an all-cash transaction, subject to customary adjustments, will be funded through a combination of existing cash reserves and bank financing. The transaction is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and other customary closing conditions. Consistent with its proven value creation focus, Galderma plans to increase commercial investment during the first year of ownership to strengthen the foundation for renewed growth beginning in the second year following closing. The transaction is expected to be slightly dilutive to the Group’s Core EBITDA margin in 2027 and to achieve a margin broadly comparable with the Group’s from 2028 onwards. The acquisition is expected to be Core EPS neutral in the first full year following closing and to be in line with Galderma’s commitment to a solid investment grade credit rating. Integration and one-time costs of approximately 50-60 million USD are expected in total over the first two years of the acquisition.

Outlook

Galderma entered the fourth quarter with strong momentum, supported by its robust financial profile and growing position as a public company. This was reflected during the third quarter by its inclusion in the Swiss Market Index (SMI) on September 21, 2026, and an upgrade by S&P Global Ratings to BBB+, with the rating confirmed following the announced acquisition of ZO Skin Health. Galderma continues to capitalize on growth opportunities across its existing portfolio, complemented by innovation and further increasing penetration in fast-growing, attractive markets.

With a stronger-than-anticipated trajectory in the first nine months, especially in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators, Galderma is raising its full-year 2026 net sales growth guidance to 22.5-23.5% at constant currency, from 19-21% previously; Fillers and Biostimulators full-year growth is expected to be broadly in line with year-to-date growth at constant currency. Galderma also confirms its Core EBITDA margin guidance of approximately 26% at constant currency, as it continues investing behind growth opportunities.

Guidance excludes the potential effects of the ZO Skin Health acquisition, expected to close in the fourth quarter of 2026 or early 2027. There is also no impact expected in 2026 from the recently enacted ‘Section 232’ tariffs on Nemluvio imported into the U.S. from the EU. While guidance is at constant currency, based on spot rates at the end of September 2026, foreign exchange is expected to have a positive impact on net sales and Core EBITDA absolutes. The evolution of Galderma’s exposure to key foreign exchange currency pairs is available in the Appendix.

Webcast details

Galderma will host a trading update call today at 15:30 CET to discuss nine-month results and respond to questions from financial analysts. Investors and the public may access the webcast by registering on the Galderma Investor Relations website at https://investors.galderma.com/events-presentations, a recording will also be made available after the event.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

Appendices

Appendix 1: Q3 year-to-date 2026 net sales by product category and geography

 

 

 

Net sales

 

Year-on-year growth

In million USD

Q3 YTD 2025

Q3 YTD 2026

 

Constant

currency

Reported

Group total

3,737

4,765

25.1%

27.5%

By product category

 

 

 

 

 

Injectable Aesthetics

1,871

2,174

 

13.2%

16.2%

Neuromodulators

1,053

1,259

 

16.9%

19.6%

Fillers & Biostimulators

818

914

8.5%

11.7%

Dermatological Skincare

1,063

1,244

16.2%

17.1%

Therapeutic Dermatology

804

1,347

64.4%

67.7%

of which Nemluvio

263

735

 

>100%

>100%

By geography

 

 

 

 

 

International

2,157

2,636

 

18.0%

22.2%

U.S.

1,580

2,130

 

34.7%

34.7%

Appendix 2: Q3 2026 net sales by product category and geography

 

 

 

 

 

Net sales

 

Year-on-year growth

In million USD

Q3 2025

Q3 2026

 

Constant

currency

Reported

Group total

1,289

1,632

26.0%

26.6%

By product category

 

 

 

 

 

Injectable Aesthetics

631

736

 

15.4%

16.7%

Neuromodulators

346

433

24.1%

25.1%

Fillers & Biostimulators

285

303

4.8%

6.4%

Dermatological Skincare

344

396

15.6%

15.4%

Therapeutic Dermatology

315

499

58.9%

58.5%

of which Nemluvio

132

302

 

>100%

>100%

By geography

 

 

 

 

 

International

748

876

 

16.2%

17.2%

U.S.

542

755

39.4%

39.4%

Appendix 3: Overview of foreign exchange rate exposure

 

Exchange rates for top FX impacts, compared to the USD

 

FX rates compared to USD

FY 2025

average rate

 

June 2026

closing rate

 

September 2026

closing rate

AUD

0.6448

 

0.6870

 

0.6972

BRL

0.1790

 

0.1927

 

0.1922

CHF

1.2058

 

1.2352

 

1.1988

CNY

 

0.1391

 

0.1471

 

0.1492

EUR

 

1.1297

 

1.1392

 

1.1336

INR

 

0.0115

 

0.0106

 

0.0104

MXN

 

0.0521

 

0.0572

 

0.0553

 

 

 

 

 

 

 

Simulation of FX impact for 2026 full-year absolute figures4

 

 

 

 

 

Net sales

 

+137 bps

 

+143 bps

 

 

Core EBITDA

 

+118 bps

 

+134 bps

Notes and references

Note: Due to rounding numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures. All ratios, subtotals and variances are calculated using the underlying amount rather than the presented rounded amount.

  1. Constant currency year-on-year growth is defined as the annual growth rate of net sales excluding the impact of exchange rates movements. The impact of changes in foreign exchange rates are excluded by translating all reported revenues during the two periods at average exchange rates in effect during the previous year.
  2. Core EBITDA is defined as EBITDA excluding the following items that are deemed non-core: acquisition and disposal; integration and carve-out related income and expenses; onerous contracts; business disposal gains and losses; litigation related items as well as impairment of PPE and intangible assets. In addition, non-Core items include other income and expense items that management considers non-Core, as well as restructuring and reorganization items expected to accumulate within approximately a year to be over a 2 M USD threshold. Items that management considers non-Core may include, but are not limited to carve-out and build-up-related project costs as well as post-acquisition-related accounting impacts.
  3. IQVIA, with reported prescription data not fully capturing all areas of demand growth (such as expansion within VA/DoD systems, integrated delivery networks, large health systems, and specialty distribution channels).
  4. Factors in the simulation of all foreign exchange rate exposures, including for currencies not listed in the table of exchange rates for top FX impact.

Forward-looking statements

Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “plans”, “targets”, “aims”, ” believes”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “continues”, “should” and similar expressions. These forward-looking statements reflect, at the time, Galderma’s beliefs, intentions and current targets/ aims concerning, among other things, Galderma’s results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management’s current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma’s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.

Contacts

For further information:


Media


Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com
+41 76 210 60 62

Investors


Emil Ivanov

Head of Strategy, Investor Relations and ESG

emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com
+41 21 642 76 43

CorTec Brain Interface Electrodes Record Stable Signals for More Than Four Years

CorTec GmbH

/ Key word(s): Study results

CorTec Brain Interface Electrodes Record Stable Signals for More Than Four Years

21.10.2026 / 14:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


CorTec Brain Interface Electrodes Record Stable Signals for More Than Four Years

Peer-reviewed data from the 10th Graz BCI Conference show four years of electrode durability and signal stability in non-human primates — the longest observation period to date for CorTec’s electrode platform, which also powers the Brain Interchange system now in clinical evaluation at the University of Washington

Freiburg, Germany, October 21, 2026 — CorTec GmbH, a pioneer in fully implantable brain-computer interfaces (BCI), today announced peer-reviewed preclinical data showing robust neural recordings from its cortical surface electrodes for more than four years. The data come from two non-human primates (Macaca mulatta) implanted at Weill Cornell Medicine in New York with micro-electrocorticography (µECoG) arrays manufactured by CorTec in Freiburg. In the animal still under study, 63 of 64 electrode contacts continue to deliver meaningful signals more than four years after implantation. The results were presented at and published in the Proceedings of the 10th Graz Brain-Computer Interface Conference in September 2026.

Long-term stability matters to patients. Each replacement surgery adds risk. A BCI earns trust and a place in clinical care only when one implant serves for years or even decades.

What the study shows

Researchers at Weill Cornell Medicine and CorTec recorded activity from prefrontal and premotor cortex while the animals performed a visual-motor reaction task, comparing recordings from three time points up to day 1,361 after implantation. Spatial patterns and spectral characteristics stayed stable and consistent across the full period. The recordings reliably showed differences between an alert, task-engaged state and a drowsy state — the type of difference a decoder, an algorithm used to classify and interpret brain signals, relies on.

In the animal still under study, one of 64 contacts stopped working after about 14 months; the remaining 63 continue to record more than four years after implantation, and additional recordings are obtained regularly. The first animal, implanted with a smaller eight-contact array, kept all contacts functional until the planned end of its study. Across both animals, no further contact has failed.

“We see the same brain signatures on day 176 and more than three and a half years later,” said Dr. C. A. Gkogkidis, Head of Clinical Business Development at CorTec and first author of the study. “A chronic BCI needs two things: long-term stability of materials and signals, and the ability to record meaningful, potentially decodable activity over years. Our data meet both. However, the current study is a snapshot of a larger data set; follow-up analysis will reveal the full picture.”

“The stability and longevity of the cortical recordings have advanced our understanding of central thalamic deep brain stimulation (CT-DBS), an investigational therapy aimed at restoring cognitive function following traumatic brain injury,” said Jonathan L. Baker PhD, Assistant Professor of Neuroscience, Weill Cornell Medicine.

From electrode to system to patient

The arrays rest on the dura, the protective membrane over the brain, and do not penetrate brain tissue. CorTec manufactures them in its Freiburg cleanrooms from medical-grade silicone and platinum-iridium — the same materials and methods used for the electrodes of Brain Interchange, CorTec’s fully implantable, wireless BCI system. The durability evidence now spans three levels:

  • Electrode arrays. More than four years of stable recordings in non-human primates (this study).
  • Complete wireless system. More than 500 days of stable recordings in non-human primates, published in Nature Scientific Data (2025). The new data more than double this.
  • In the clinical setting. The complete Brain Interchange system remained implanted for nine months in the first participant of the NIH-funded stroke rehab study at the University of Washington (UH3NS121565; NCT06506279) and was then safely removed, as planned per the study protocol.

“Durability decides whether a brain implant becomes a therapy,” said Dr. Frank Desiere, CEO of CorTec. “Our electrodes rest on the brain surface and never enter brain tissue. Four years of stable signals show this approach holds up over time. With two FDA Breakthrough Device Designations, entry into the FDA TAP program and three patients implanted in Seattle this year, Brain Interchange has moved from technology to a clinical research platform for stroke, paralysis and epilepsy.”

Brain Interchange is being investigated as a therapeutic BCI to support motor recovery after stroke and as an assistive BCI to restore control of a computer cursor — both on identical hardware.

Brain Interchange at a glance

  • Non-penetrating, wireless, battery-free. Electrodes rest on the brain surface; an external head piece powers the implant through the skin by inductive link.
  • Bidirectional and closed-loop. Records brain activity and delivers targeted stimulation on the same 32 channels, with continuous streaming of raw brain data.
  • Two FDA Breakthrough Device Designations (2026). Stroke motor rehabilitation (April) and communication in people with non-progressive quadriplegia (August). To CorTec’s knowledge, the only BCI designated for stroke motor rehabilitation.
  • Clinical footprint. Three patients implanted in the NIH-funded, FDA-authorized IDE stroke study at the University of Washington (UH3NS121565; NCT06506279), including the first reported volitional BCI control by a person with chronic stroke (Graz BCI Conference, September 2026). 13 patients enrolled in the epilepsy study at Mayo Clinic (NCT05439655). More than 50 CorTec cortical electrodes implanted in humans over more than a decade.
  • Regulatory record. FDA 510(k) clearance for AirRay subdural cortical electrodes (2019), FDA IDE (2024), FDA Total Product Life Cycle Advisory Program, TAP (2026).

Publications

  • Gkogkidis, C. A., Schuettler, M., Ulloa, M., Ryou, J. W., Purpura, K. P., Baker, J. L. (2026). Epidural micro-ECoG provides a robust interface to the cortex over 4 years in non-human primates. Proceedings of the 10th Graz Brain-Computer Interface Conference 2026, 547. doi:10.3217/978-3-99161-093-9-094
  • Sarma, D., Cho, H., … Ojemann, J. G., Herron, J. A. (2026). Volitional neural control with the CorTec Brain Interchange by an individual with chronic stroke. Proceedings of the 10th Graz Brain-Computer Interface Conference 2026, 588. doi:10.3217/978-3-99161-093-9-101
  • Yang, H., … Yanagisawa, T. (2025). Nature Scientific Data. nature.com/articles/s41597-025-06359-w

About CorTec

CorTec GmbH is a clinical-stage neurotechnology company founded in 2010 in Freiburg, Germany, with one purpose: to restore independence to people with neurological conditions. CorTec is developing Brain Interchange™, a fully implantable bidirectional brain-computer interface (BCI) platform currently in FDA-authorized clinical evaluation in the United States, making CorTec the first European company to reach this stage. The device holds two FDA Breakthrough Device Designations: one for stroke motor rehabilitation (April 2026) and a second for communication (August 2026), and it has been admitted to the FDA’s Total Product Life Cycle Advisory Program (TAP). CorTec also operates a revenue-generating contract development and manufacturing (CDMO) business, supplying active implantable technology to partners across the global neurotechnology field, extending the reach of these technologies beyond what any single company could achieve alone.

CorTec — fighting neurological conditions with implantable neurotechnology.

Media assets

Participant video, UW Medicine (2 min): https://www.youtube.com/watch?v=xNXBe8P4Tz8

Company introduction: https://youtu.be/b-lHrH0IqQA

Webinar, Prof. Dr. Jeffrey G. Ojemann on three-patient results: https://youtu.be/Lh5KSRP2YjQ

 

Contact:
CorTec GmbH
Benedikt Kaiser – Head of Marketing
pr@cortec-neuro.com
www.cortec-neuro.com
Phone: +49 (0)761 70 888 200
Neuer Messplatz 3
79108 Freiburg – Germany
Media Support:
MC Services AG
Katja Arnold, Dr. Johanna Kobler, Kaja Skorka
cortec@mc-services.eu
Phone: +49 (0)89 210 228-0

 

Disclaimer: Brain Interchange is an investigational device and has not received FDA marketing authorization. The four-year and 500-day results come from preclinical studies in non-human primates. The 2019 FDA 510(k) clearance (K183437) covers AirRay subdural cortical electrodes for temporary use (less than 30 days) and does not cover Brain Interchange. AirRay is not currently available for clinical use in the United States. FDA Breakthrough Device Designation does not change the requirements for marketing authorization and does not guarantee approval. Statements regarding CorTec’s plans, future indications and commercialization intentions are forward-looking and subject to risks and uncertainties.


21.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2419588  21.10.2026 CET/CEST

Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting

Issuer: Immunic AG

/ Key word(s): Conference/Study results

Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting

21.10.2026 / 13:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting

– New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes Observed During the Double-Blind Period With Continued Vidofludimus Calcium Treatment; Safety and Tolerability Profile Appeared Consistent With That Observed in the Double-Blind Period –

– New Preclinical Data Suggest Nurr1-Dependent Neuronal Survival and Neuroprotective Effects Beyond DHODH Inhibition – 

– Exploratory and Post-hoc CALLIPER Analyses Show Significant Reductions in EBV-Specific T-Cell Receptor Signatures; Observed Reductions Associated With Increased Symbol Digit Modalities Test (SDMT) Scores – 

– Post-hoc Analysis of CALLIPER Using a Proposed Novel Disability Measure Suggests Overall Benefit of Vidofludimus Calcium in Progressive Multiple Sclerosis Patients –

NEW YORK, October 21, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that new clinical, biomarker, and preclinical data for its lead investigational asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), are being presented across four poster presentations at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting, taking place October 21-23, 2026, in Toronto. All posters are available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations. Additionally, the team is available throughout the event at booth #516.

“The data presented at MSToronto2026 provide complementary clinical and mechanistic evidence supporting the differentiated profile of vidofludimus calcium across the multiple sclerosis (MS) spectrum,” said Erik Lundgren, Chief Executive Officer of Immunic. “Importantly, the new CALLIPER open-label extension (OLE) analyses provide favorable long-term follow-up of the disability signals observed during the double-blind treatment period, while the Nurr1, Epstein-Barr virus (EBV), and disability endpoint analyses provide additional insight into the biology of disease progression and how treatment effects may be more comprehensively measured. Together, these findings further support the clinical and scientific rationale for our planned Phase 3 program in progressive MS, which we expect to initiate later this year, while we also approach the top-line results from our fully enrolled Phase 3 ENSURE trials in relapsing MS, expected by year-end 2026.”

New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes

Poster Title: Evaluation of Disability Outcomes from the Open-Label Extension of CALLIPER: A Phase 2 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

  • Lead Author: Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio and Coordinating Investigator of the CALLIPER trial
  • Presentation: Paper Poster, Poster Number P0387
  • Date and Time: Poster Session 1, Wednesday, October 21, 2026, 4:30 – 6:30 pm ET

New analyses of the Phase 2 CALLIPER trial showed that the favorable trends on disability outcomes observed during the double-blind main treatment period were maintained during the OLE phase among participants who continued vidofludimus calcium treatment. Only 6.5% of patients discontinued through the January 27, 2026 data cutoff, with a safety and tolerability profile that appeared consistent with that observed in the double-blind period.

Preclinical Models Suggest Nurr1-Dependent Neuronal Survival and Neuroprotective Effects

Poster Title: Vidofludimus Calcium Requires Nurr1 to Promote Neuronal Survival In Vitro and Is Associated with Neuroprotective Effects in Murine Models of Multiple Sclerosis

  • Lead Author: Mehrnoosh Jafari, Senior Manager Translational Pharmacology at Immunic
  • Presentation: Paper Poster, Poster Number P1273
  • Date and Time: Poster Session 2, Thursday, October 22, 2026, 4:30-6:30 pm ET

New preclinical findings across multiple models suggest that vidofludimus calcium promotes neuronal survival under apoptotic stress conditions, an effect requiring Nurr1, and in addition reduces microglia-driven neuronal loss, supporting direct and indirect neuroprotective mechanisms. Under in vitro apoptotic conditions, vidofludimus calcium promoted neuronal survival, an effect not observed with teriflunomide, suggesting that the observed pro-survival effect involves mechanisms beyond DHODH inhibition.

Vidofludimus calcium also reduced disease severity and plasma neurofilament light (NfL) chain levels in murine experimental autoimmune encephalomyelitis (EAE) models, and increased brain-derived neurotrophic factor (BDNF) levels and expression of Nurr1-regulated target genes, providing additional evidence consistent with activation of Nurr1-pathways.

Taken together, these findings provide further preclinical evidence of the profile of vidofludimus calcium on pathways associated with neuroprotective effects.

Exploratory and Post-hoc CALLIPER Analyses Link Reduced EBV-Specific T-Cell Signatures with Improved Cognitive Performance as Measured by the Symbol Digit Modalities Test

Poster Title: Anti-EBV T-cell Receptor Repertoire Reduction Is Linked to Enhanced Cognitive Performance in Progressive Multiple Sclerosis: Evidence from the Phase 2 CALLIPER Trial with Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor

  • Lead Author: Amelie Schreieck, Ph.D., Senior Manager Biomarker Development at Immunic
  • Presentation: ePoster, Number EP2473
  • Date and Time: ePoster screens within the congress center and on the congress platform for the duration of the congress

An exploratory CALLIPER analysis found that vidofludimus calcium significantly reduced EBV-specific TCRβ chain (TRB) sequence matches versus placebo-treated patients (-0.65 matches; p=0.0004), while influenza A-specific matches were unchanged (+0.08; p=0.5983), suggesting an EBV-selective rather than generalized effect on the T-cell repertoire, consistent with a lowered rate of EBV reactivations. Across all patients, reductions in EBV-specific TRB matches were associated with improved Symbol Digit Modalities Test (SDMT, broadly used to assess processing speed) scores, as assessed in a post-hoc analysis. Safety and tolerability data from the CALLIPER trial are summarized below.

These exploratory findings support further investigation of the relationship between EBV-related immune activity and cognitive function in progressive MS.

Novel CALLIPER Analyses Evaluate Disability Improvement and Worsening Together

Poster Title: Bidirectional Disability Changes in Progressive Multiple Sclerosis Patients: a Proposed Endpoint to Capture Full Treatment Effects

  • Lead Author: James Myles, Global Head of Biostatistics at Immunic
  • Presentation: ePoster, Number EP2205
  • Date and Time: ePoster screens within the congress center and on the congress platform for the duration of the congress

Traditional progressive MS analyses have focused primarily on delaying confirmed disability worsening, with improvement often not captured fully or assessed separately. This analysis evaluates two novel statistical models, Confirmed Disability Change (CDC) and Generalized Pairwise Comparisons (GPC), as proposed methods to integrate confirmed disability worsening and improvement into a single statistical analysis measure.

Applying both methods to CALLIPER post-hoc, progressive MS patients treated with vidofludimus calcium appeared more likely to have positive outcomes as compared to placebo, suggesting these methods may capture the true bidirectional disability trajectory of patients. The CDC method fits an ordinal logistic regression model to three ordered categories of confirmed disability change. Using data from the CALLIPER trial, patients treated with vidofludimus calcium were 2.47 times more likely to experience 24-week confirmed disability improvement (CDI) (nominal p=0.037), and a positive CDC (nominal p=0.042). The GPC method compares all pairs of patients to determine which patient had a better outcome as measured by improvement, stability, or slowed worsening on the Expanded Disability Status Scale (EDSS) score. By this method, patients on vidofludimus calcium were 1.5 times more likely to have a better outcome than those who received placebo, a statistically significant and clinically meaningful result (p=0.042).

These outcomes support further evaluation of a bidirectional endpoint designed to capture treatment effects across both disability worsening and improvement.

About Vidofludimus Calcium (IMU-838) and the CALLIPER Trial

Vidofludimus calcium (IMU-838) is an investigational oral small molecule activating nuclear receptor-related 1 (Nurr1) and selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). It is currently being evaluated in the Phase 3 ENSURE trials in relapsing multiple sclerosis (MS). More than 3,500 individuals have been exposed to vidofludimus calcium, to date.

The Phase 2 CALLIPER trial randomized 467 patients with primary or secondary progressive MS 1:1 to 45 mg once-daily vidofludimus calcium or placebo. While the primary endpoint of percent brain volume change (PBVC) was not met, exploratory imaging and clinical outcomes showed directionally favorable signals. Rates of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) were similar to placebo (69.4% vs. 68.5% and 8.1% vs. 6.5%, respectively), with no new safety signals and no Hy’s law range cases observed. Among the 387 participants who entered the OLE phase, 44.4% experienced at least one TEAE, including 5.7% who experienced a serious TEAE. Liver-related TEAEs occurred in 3.1% of participants, and TEAEs leading to discontinuation in 1.8%.

Vidofludimus calcium (IMU-838) is an investigational medicinal product that has not been approved or authorized by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other regulatory authority for any indication in any jurisdiction. Its safety and efficacy have not been established. Any clinical, biomarker, or preclinical findings described reflect investigational data and are not intended to suggest that vidofludimus calcium is safe or effective for any use.

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive MS is expected later in 2026. Vidofludimus calcium has already shown therapeutic potential and a favorable safety and tolerability profile in Phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com. 

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory Phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
LifeSci Advisors
Joyce Allaire
immunic@lifesciadvisors.com

US Media Contact
Real Chemistry
media@imux.com


Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Formycon and Biocelys Combine Complementary Development and Manufacturing Expertise in New Biosimilar Project FYB286

Formycon AG

/ Key word(s): Alliance

Formycon and Biocelys Combine Complementary Development and Manufacturing Expertise in New Biosimilar Project FYB286

21.10.2026 / 06:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Press Release // October 21, 2026

 

Formycon and Biocelys Combine Complementary Development and Manufacturing Expertise in New Biosimilar Project FYB286
 

  • FYB286 expands Formycon’s biosimilar pipeline with a promising development project in an attractive niche indication
  • Combining Formycon’s development excellence with the manufacturing expertise of South American specialty pharma company Biocelys enables a highly competitive cost structure
  • Upfront financing by Santo Biosimilar GmbH, a company of the ATHOS Group, reflects its continued commitment to biosimilars and strong confidence in the capabilities of both collaboration partners

 

Planegg-Martinsried, Germany / Montevideo, Uruguay – Formycon AG (FSE: FYB, Prime Standard, “Formycon“) and Biocelys S.A. (“Biocelys”), a company of the ATHOS Group, today announced the launch of a collaboration to develop the biosimilar candidate FYB286. The partnership combines Formycon’s proven expertise in biosimilar development with Biocelys’ state-of-the-art manufacturing infrastructure. The project is being financed upfront by Santo Biosimilar GmbH (“Santo”), an affiliated company of ATHOS KG (“ATHOS”). ATHOS is Formycon’s largest anchor shareholder and indirectly controls both Santo Biosimilar GmbH and Biocelys S.A.

Under the agreement with Santo, Formycon will receive arm’s-length compensation for its development services and will participate in future revenues of Santo with a low double-digit percentage share. The technologically demanding development program targets a niche indication with attractive growth potential, making FYB286 a strategically compelling addition to Formycon’s value-focused biosimilar portfolio.

Dr. Stefan Glombitza, CEO of Formycon AG, commented: “Biosimilars for niche-busters1 combine two key elements: they meet the strong demand for high-quality biologic therapies for relatively rare conditions while creating an attractive market opportunity. For FYB286, we expect demand to increase substantially, particularly in emerging markets. Together with Biocelys, we can achieve both objectives: help patients with rare diseases and tap into a new market. Biocelys and Formycon complement each other perfectly by combining state-of-the-art manufacturing capabilities with our extensive expertise and operational excellence in biosimilar development. With Biocelys as part of our network of strategic manufacturing partners, we are strengthening our supply capabilities well beyond the FYB286 project and setting another important cornerstone in our FYB4Growth strategy.”

With FYB4Growth, Formycon is pursuing a growth strategy based on four strategic pillars focused on sustainable value creation: An intelligent portfolio strategy, geographic diversification of target markets, outstanding scientific excellence, and consistent cost efficiency form the foundation of Formycon’s robust and growth-oriented business model.

“In line with our vision to produce high-quality pharmaceuticals from Latin America for patients around the world, our collaboration with Formycon on the FYB286 project marks an important milestone. Our Montevideo site not only features state-of-the-art manufacturing facilities but also the expertise required to manufacture complex biologic molecules. Together with Formycon as our project partner, we will improve access to a much-needed therapy, particularly in regions where patient needs remain largely unmet,” said Adive Carrasco, Managing Director of Biocelys S.A.

“As long-term investors, we support FYB286 as a collaboration model that brings together the complementary strengths of our portfolio companies. The combination of scientific development excellence and modern biopharmaceutical manufacturing provides a solid foundation for executing projects of this kind efficiently and with clear focus on value creation. By providing the upfront financing, we are creating the framework that enables Formycon and Biocelys to implement the project independently and in partnership,” added ATHOS KG.
 

————————

1 We define a “niche-buster” as a drug for a niche indication with global annual sales in the low- to mid-single-digit billion-dollar range

 

About Formycon:
Formycon AG is a listed, independent developer of biosimilars based in Planegg-Martinsried, one of the leading life science locations in Europe, just outside Munich, Germany. Its 200 employees from 27 countries cover the entire development chain, from laboratory analysis through manufacturing and clinical testing to the documents for approval. Three Formycon biosimilars are approved in ophthalmology and immunology and are marketed worldwide through commercialization partners. Four further candidates are in development, among them biosimilars to two of the best-selling biologic medicines in the world. With its products, Formycon makes highly effective therapies affordable for more people.

Formycon AG is listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at: https://www.formycon.com/en/

About #FYB4Growth:
With FYB4Growth, Formycon is pursuing a growth strategy based on four strategic pillars aimed at creating sustainable value. First, geographic diversification: in addition to Europe and the U.S., Formycon is strategically expanding into high growth regions such as MENA, APAC and Latin America through strong regional partners. Second, a smart portfolio strategy: Formycon relies on an intelligent portfolio strategy that specifically combines blockbuster molecules with selected niche products and creates the foundation for sustainable value generation through efficient regulatory development pathways. Third, excellence and innovation: Formycon positions itself as a technological and regulatory development powerhouse, creating clear competitive differentiation through innovative product solutions and new regulatory approaches. Fourth, consistent cost efficiency: streamlined processes, optimized development structures and the increased use of digital technologies are designed to enhance the scalability of the business model and strengthen Formycon’s competitiveness over the long term. Find out more at: https://www.fyb4growth.com

About Biocelys:
Biocelys S.A. (“Biocelys”), based at Parque de las Ciencias in Canelones, Uruguay, is a biopharmaceutical company for the development and manufacture of biotechnological drug substances. Its focus is on monoclonal antibodies and related recombinant proteins from mammalian cell culture, covering the process from cell bank through cell culture and purification to the released drug substance. The facility is newly built to current technical standards and designed for manufacturing in line with international GMP standards.

Biocelys is a company of the ATHOS Group. The company pursues the vision of making high-quality biopharmaceuticals available from Latin America to patients worldwide. Alongside its own process development, Biocelys performs technology transfers for partners and supports projects from process transfer through validation to commercial supply. Adive Carrasco is Managing Director of Biocelys S.A.

About Biosimilars:
Biosimilars are successor products to biologic medicines. They are not copies; each one is developed from the ground up and must demonstrate to the health authorities that it has no clinically meaningful differences from the reference product in terms of safety and efficacy. According to the IQVIA Institute, 118 biologic medicines with sales of USD 232 billion will lose their exclusivity in the US alone by 2034, and for only twelve of them is a biosimilar in development. In Europe, biosimilars have saved EUR 75 billion and made more than seven billion days of treatment possible.

 

Contact
 
Dr. Jörg Allgäuer
Investor Relations &
Corporate Communications
+49 89 864667‑107
Elena Straßner
Investor Relations
+49 89 864667‑485
 
Thorsten Ladda
Corporate Communications
+49 89 864667‑150
 
Formycon AG
Fraunhoferstr. 15 · 82152 Planegg-Martinsried · Germany
ir@formycon.com · www.formycon.com

 

 Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.


21.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried
Germany
Phone: +49 89 864667 100
Fax: +49 89 864667 110
E-mail: ir@formycon.com
Internet: www.formycon.com
ISIN: DE000A1EWVY8, NO0013586024
WKN: A1EWVY, A4DFJH
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX; Oslo
LEI Code: 39120005TZ76GQOY8Z19
EQS News ID: 2418978

 
End of News EQS News Service

2418978  21.10.2026 CET/CEST

Cellbox Solutions Completes Series A Financing with Total Proceeds of EUR 5 Million

Cellbox Solutions GmbH

/ Key word(s): Financing

Cellbox Solutions Completes Series A Financing with Total Proceeds of EUR 5 Million

20.10.2026 / 10:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Cellbox Solutions Completes Series A Financing with Total Proceeds of EUR 5 Million

  • Final closing of the Series A marks the next phase of Cellbox Solutions’ commercial development
  • New investors add international reach, sector expertise and strategic support
  • Funding will support the expansion of warm-chain logistics services and international growth

Cologne, Germany, October 20, 2026 – Cellbox Solutions, a warm-chain logistics technology company, has completed the final closing of its Series A financing, bringing the total proceeds to EUR 5 million. With this additional capital, the company is further developing its business model and expanding its offering to include integrated logistics solutions for cells, tissues, organoids, and other sensitive biological materials.

The financing marks the next phase in the company’s commercial growth, and will help leverage the established technological, product-related, and regulatory advances Cellbox Solutions has achieved in recent years. A key focus is building on the company’s specialized transport capabilities to link controlled transport under physiological conditions even more closely with additional logistics and service offerings.

Following the first closing of approximately EUR 3.5 million in March 2026, Cellbox Solutions has attracted additional investors. The new investors include members of the Baltic Business Angels Invest GmbH, a Canadian family office, and an undisclosed investor with extensive experience in pharmaceutical logistics. Existing investors NRW.BANK and Fraunhofer Venture also participated in the financing. Companisto led the first closing.

Cellbox™ Go and Cellbox™ Shipper make up the core of the company’s technology platform. Both incubators provide controlled temperature and CO₂ conditions during ground and air transport and are already used internationally in research and cell therapy applications.

With over 400 Cellbox systems currently on the market, a growing number of customer relationships and a regulatory foundation that includes Drug Master Files for the CellboxTM product family, the company is well positioned to expand its commercial offering. This includes combining CellboxTM systems with rental and transport options, as well as recurring services such as monitoring, fleet management, and shipment coordination. The aim is to provide customers with even greater flexibility and comprehensive support for their logistics processes in the future.

“Over the past years, we have built a strong foundation for the controlled transport of living biological materials,” said Prof. Dr. Kathrin Adlkofer, Founder and CEO of Cellbox Solutions. “With the successful completion of our Series A round, we are now expanding our established warm-chain technology platform into a broader offering for physiological logistics. This will allow us to support customers more comprehensively across their logistics workflows and expand our presence in key international markets.”

To this end, the company is continuing to expand its activities in Europe, Asia, and North America and is increasingly focusing on strategic partnerships with logistics providers.

“Completion of the Series A gives us additional resources to scale the commercial model behind our technology. By expanding rental and recurring service offerings and combining them with transportation, monitoring, and complementary logistics services, we can build longer-term customer relationships and a more scalable service model across markets. Our focus is now on translating the strength of the Cellbox platform into sustainable commercial growth,” concluded Dr. Bernd Muehlenweg, CBO and CFO of Cellbox Solutions.

 

About Cellbox Solutions GmbH

Founded in 2017, Cellbox Solutions GmbH is a Germany-based warm-chain logistics technology company providing innovative solutions for the global healthcare and life sciences industries to transport sensitive biological materials and therapeutics that cannot be frozen and require controlled physiological conditions. The company’s portable CO₂ incubator platform, Cellbox™, creates a regulated environment for the transport of living cells, organoids, tissues, and other advanced biological materials. Temperature and CO₂ levels are individually adjustable to ensure reproducible incubation conditions throughout shipment. Cellbox™ systems are deployed globally and support research, clinical, and advanced therapy applications. Building on its established technology platform, Cellbox Solutions is expanding its offering toward integrated physiological logistics solutions that combine controlled transport with rental, monitoring and related recurring services. For more information, please visit www.cellbox-solutions.com or follow Cellbox Solutions on LinkedIn.
 

Contact
Cellbox Solutions GmbH
Prof. Dr. Kathrin Adlkofer, CEO               
office@cellbox-solutions.com
+49 (0) 40 883 67 85 3
Media Contact
MC Services AG
Dr. Cora Kaiser
cellbox@mc-services.eu
+49 (0) 89 210 228 60
 

 


20.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2418342  20.10.2026 CET/CEST

BioVersys announces publication of BV100 lung penetration and drug interaction data in two leading peer-reviewed antimicrobial journals

 

 Basel, Switzerland. October 20, 2026, 7am CET

  • International Journal of Antimicrobial Agents publishes data showing that BV100 reaches concentrations in lung fluid and alveolar macrophages approximately 35-fold and over 300-fold higher, respectively, than in plasma, providing a strong pharmacological rationale for BV100 use in severe CRAB pneumonia
  • Journal of Antimicrobial Chemotherapy publishes data showing BV100 is a mild CYP3A inducer and a mild substrate for CYP3A inhibitors, a milder drug interaction profile than rifampicin, supporting its use alongside the many medicines given to critically ill patients
  • Both Phase 1 datasets form part of the clinical solid pharmacology foundation of RIV-TARGET, the ongoing Phase 3 registration trial of BV100 in hospital- and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC); trial enrollment is ongoing, with topline data read-out anticipated for early 2028

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today the publication of two Phase 1 clinical pharmacology studies of BV100, its lead clinical asset, in two leading peer-reviewed journals in the field of antimicrobial therapy: the International Journal of Antimicrobial Agents, the official journal of the International Society of Antimicrobial Chemotherapy, and the Journal of Antimicrobial Chemotherapy, the official journal of the British Society for Antimicrobial Chemotherapy.

Dr. Glenn Dale, Chief Development Officer of BioVersys and co-author of the publications, commented: “These two papers address the questions that matter most for an intravenous antibiotic in critically ill pneumonia patients. BV100 has very good distribution in lung fluid and alveolar macrophages, and its drug-interaction profile is mild and manageable. We are pleased to share these data with the infectious disease and critical care community as we continue to enroll patients in our Phase 3 study RIV-TARGET.”

Dr. Marc Gitzinger, Chief Executive Officer and founder of BioVersys, added: “Carbapenem-resistant Acinetobacter baumannii represents one of the highest medical needs in infectious disease, and patients fighting these life-threatening infections have very few options. These data continue to strengthen the growing scientific basis for BV100 therapy in CRABC pneumonia and bring us a step closer to delivering a much-needed new treatment option to patients and the physicians who care for them.”

International Journal of Antimicrobial Agents: lung penetration study

The paper, entitled “Pulmonary Penetration of Intravenous Rifabutin in Healthy Participants: A Multiple-Dose Pharmacokinetic Study,” was published in the International Journal of Antimicrobial Agents (DOI: 10.1016/j.ijantimicag.2026.108014). In 36 healthy male participants receiving BV100 (intravenous rifabutin) 300 mg every 12 hours for four days, concentrations of rifabutin in lung fluid and alveolar macrophages exceeded plasma concentrations at every time point, with median penetration ratios of approximately 35-fold and over 300-fold, respectively, and repeated dosing was well tolerated. The authors conclude that these pulmonary exposures provide a strong pharmacological rationale for further clinical evaluation of BV100 in severe CRAB pneumonia.

Journal of Antimicrobial Chemotherapy: drug-drug interaction studies

The paper, entitled “BV100 (rifabutin IV) drug interaction studies in healthy subjects with index CYP450 3A probes midazolam and itraconazole,” was published in the Journal of Antimicrobial Chemotherapy (DOI: 10.1093/jac/dkag317). Across two Phase 1 studies, BV100 was shown to be a mild CYP3A inducer, reducing midazolam exposure by approximately 47%, and a mild substrate for CYP3A inhibitors, with rifabutin exposure increasing 1.3- to 1.7-fold with itraconazole. This is a milder interaction profile than that of rifampicin, a strong CYP3A inducer, and BV100 was safe and well tolerated in both studies.

BV100 is currently studied in two clinical trials: the pivotal Phase 3 global registrational trial, RIV-TARGET and the open-label Phase 2b differentiation trial, RIV-CARE in collaboration with ADVANCE-ID. In September 2026, BV100 was granted Fast Track Designation by the US FDA, under the Qualified Infectious Disease Product (QIDP) Designation received in 2019.

Pentixapharm Holding AG: 2026 Earnings Guidance Raised; First-Patient Enrollment in PANDA Phase 3 Study Now Expected in the First Quarter of 2027

Pentixapharm Holding AG / Key word(s): Forecast / Full year

Pentixapharm Holding AG: 2026 Earnings Guidance Raised; First-Patient Enrollment in PANDA Phase 3 Study Now Expected in the First Quarter of 2027

19-Oct-2026 / 22:16 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014 (Market Abuse Regulation)

Pentixapharm Holding AG: 2026 Earnings Guidance Raised; First-Patient Enrollment in PANDA Phase 3 Study Now Expected in the First Quarter of 2027

  • Expected net loss for 2026 of approximately EUR 13 million (previously: approximately EUR 21.6 million)
  • Cash runway into 2028 unchanged

Berlin, October 19, 2026 – The Management Board of Pentixapharm Holding AG (ISIN DE000A40AEG0) today raised the earnings guidance for fiscal year 2026 on the basis of an updated business plan. Based on the current state of planning, the Management Board now expects a net loss of approximately EUR 13 million for full-year 2026. Previously, a net loss of approximately EUR 21.6 million had been expected.

The improvement of approximately EUR 8.6 million results from several concurrent factors, in particular cost deferrals and cost reductions as well as changes in amortization.

With regard to the reduction of cash expenses in fiscal year 2026, the following effects are to be highlighted:

  • Approximately EUR 3 million from expenses for the PANDA Phase 3 study, part of which will shift into fiscal year 2027 as a result of the agreements with service providers that have since been firmed up and the adjusted timeline of the study.
  • Approximately EUR 2 million from other effects, in particular lower personnel expenses, lower interest expenses as a result of the later drawdown under the convertible bond facility, and expenses for the acquisition of data deferred beyond the end of fiscal year 2026.

Enrollment of the first patient in the PANDA Phase 3 study is now expected in the first quarter of 2027 (previously: second half of 2026). The Company currently does not expect any material impact on the further timeline of the study.

The lower expenses also result in lower cash outflows in fiscal year 2026. The Company’s assessment remains unchanged that its available financial resources will fund operations into 2028.

In addition, there is a non-cash effect of approximately EUR 3.7 million, primarily driven by the elimination of scheduled amortization of intangible assets, which the Company is implementing on the basis of Bafin’s findings of October 2, 2026 in its consolidated financial statements for 2026 and already in its quarterly statement for the third quarter of 2026.

October 19, 2026

Pentixapharm Holding AG, Berlin

The Management Board

Contact: ir@pentixapharm.com

 

 

End of Inside Information


19-Oct-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Pentixapharm Holding AG
Robert-Rössle-Straße 10
13125 Berlin
Germany
E-mail: info@pentixapharm.com
Internet: https://www.pentixapharm.com/
ISIN: DE000A40AEG0
WKN: A40AEG
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 3912005VBOVXNDXEQZ36
EQS News ID: 2418374

 
End of Announcement EQS News Service

2418374  19-Oct-2026 CET/CEST

Cantourage Group SE: Supervisory Board Resolves to Transition to IFRS Following First-Time Requirement to Prepare Consolidated Financial Statements

Cantourage Group SE / Key word(s): Other/Strategic corporate decision

Cantourage Group SE: Supervisory Board Resolves to Transition to IFRS Following First-Time Requirement to Prepare Consolidated Financial Statements

19-Oct-2026 / 21:22 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


In connection with the Company’s first-time requirement to prepare consolidated financial statements for the 2026 financial year, the Supervisory Board of Cantourage Group SE resolved at its meeting today to transition the Company’s consolidated financial reporting from German GAAP (HGB) to International Financial Reporting Standards (IFRS).

A preliminary reconciliation of the 2025 consolidated financial figures from HGB to IFRS indicates significant positive effects on earnings and equity. These effects primarily result from differences in the accounting treatment of goodwill and share-based compensation plans.

A detailed pro forma comparison of the 2025 consolidated financial figures under HGB and IFRS will be published on the Company’s website in early November 2026, following the completion of the audit of the 2025 consolidated financial statements.

About Cantourage
Cantourage is a leading European company engaged in the production and distribution of medical cannabis preparations and cannabis-based pharmaceuticals. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to access the growing European medical cannabis market faster, more easily and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In doing so, Cantourage consistently ensures compliance with the highest European pharmaceutical quality standards.
The Company offers pharmaceutical-grade products across all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 – DE000A3DSV01 (ISIN).
 

 

End of Inside Information


19-Oct-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Cantourage Group SE
Feurigstraße 54
10827 Berlin
Germany
E-mail: info@cantourage.com
Internet: https://www.cantourage.com/
ISIN: DE000A3DSV01
WKN: A3DSV0
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate BSX
LEI Code: 3912003NCTLO6YHA9V48
EQS News ID: 2418358

 
End of Announcement EQS News Service

2418358  19-Oct-2026 CET/CEST

Immunic Appoints Jaa Roberson as Chief People Officer

Issuer: Immunic AG

/ Key word(s): Personnel

Immunic Appoints Jaa Roberson as Chief People Officer

19.10.2026 / 12:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Immunic Appoints Jaa Roberson as Chief People Officer 

– Appointment Supports Immunic’s Strategy to Build a Leading Multiple Sclerosis Organization Ahead of Potential Transition to Fully Integrated Commercial Company –

NEW YORK, October 19, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jaa Roberson as Chief People Officer (CPO), effective today. Ms. Roberson will report directly to Chief Executive Officer Erik Lundgren and will serve as a member of the executive leadership team.

The appointment represents another important step in Immunic’s strategy to assemble a team of highly qualified leaders with key experience in building a leading multiple sclerosis (MS) organization. In this newly created executive role, Ms. Roberson will lead the company’s global talent and organizational strategy, with a particular focus on attracting and developing the specialized capabilities required as Immunic prepares for its pivotal Phase 3 ENSURE read-out expected by the end of 2026, as well as potential regulatory filings and commercialization of vidofludimus calcium (IMU-838).

“Over the past several months, we have been assembling a leadership team with deep experience in MS and a track record of successfully developing and commercializing important therapies for patients,” said Erik Lundgren, Chief Executive Officer of Immunic. “Our continued goal is to build an exceptional MS organization with the right people and capabilities in place. I am thrilled that Jaa joins us at this critical time, with the pivotal Phase 3 data in relapsing MS expected by year-end and our progressive MS trial preparations advancing. Jaa will be a strategic partner on the management team helping us attract, develop, and retain world-class talent while building the structures, systems, and culture necessary for scaling from a research and development biotechnology company toward a fully integrated commercial organization.”

“I am excited to join Immunic at such an important stage in the company’s evolution,” said Jaa Roberson, Chief People Officer of Immunic. “Immunic has assembled a strong leadership team with deep experience across MS research and development, regulatory and commercialization. With the pivotal Phase 3 data approaching, my focus will be on building the broader organization and continuing to attract the specialized talent, capabilities, and culture needed to support potential regulatory approval and commercialization, while preserving the agility and focus that differentiate Immunic as a biotechnology company.”

Ms. Roberson is a people leader with more than two decades of human resources (HR) experience across the biopharma, health insurance, and retail industries, successfully leading companies through growth, transformation and change by building high performance, diverse and inclusive organizations where everyone thrives, contributes and grows to drive impactful patient and business outcomes. Most recently as Chief People Officer at Day One Biopharmaceuticals, she guided the organization to scale and grow from 37 to 200 employees while maintaining strong engagement and retention, successfully transition from clinical to commercial stage following the approval and launch of OJEMDA® (pediatric low-grade glioma), expand the pipeline into adult oncology, which included the acquisition of Mersana Therapeutics, and ultimately Day One’s acquisition by Servier. Previously, Ms. Roberson led HR at Bellicum Pharmaceuticals and at Achaogen, where she supported the companies’ expansions, pre-commercial and commercial launch preparations, as well as restructuring and workforce transitions. Earlier in her career, she spent six years at Genentech, a member of the Roche Group, as an HR Business Partner supporting commercial franchises, including the build of the Ocrevus® (MS) and Hemlibra® (hemophilia) franchises. She also held HR leadership roles of increasing responsibility at Blue Shield of California, Levi Strauss & Co. and Williams-Sonoma, Inc. Ms. Roberson holds a Bachelor of Arts from Rice University and a Master of Music in Violin Performance from the San Francisco Conservatory of Music.

The Compensation Committee of Immunic’s Board of Directors granted Ms. Roberson an initial equity option to purchase 190,000 shares of common stock of the company under the Immunic, Inc. 2026 Inducement Equity Compensation Plan (the “Options”). The Options were granted as an inducement material to Ms. Roberson’s commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). The Options will be time vested, with 25% vesting on the one-year anniversary of October 19, 2026 and the remainder vesting on a monthly basis in 36 equal installments.
 

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive MS is expected later in 2026. Vidofludimus calcium has already shown therapeutic potential and a favorable safety and tolerability profile in Phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s development programs and the targeted diseases; the potential for Immunic’s development programs to safely and effectively target diseases; preclinical and clinical data for Immunic’s development programs; the feasibility of advancing vidofludimus calcium to a confirmatory Phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company; expectations regarding the capitalization, resources and ownership structure of the company; and the executive and board structure of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.
 

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
LifeSci Advisors
Joyce Allaire
immunic@lifesciadvisors.com

US Media Contact
Real Chemistry
media@imux.com


Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.